Anchit Khanna, MD, MMedSci, PhD

Clinical Scientist
Adult Cancer Program, Prince of Wales Clinical School
Level 2, Lowy Cancer Research Centre C25
UNSW Medicine
The University of New South Wales
Sydney, NSW, 2052, Australia


Dr. Khanna, is a Clinician-Scientist who joined the Adult Cancer Program at the Lowy Cancer Research Centre in 2012. He obtained a MD/PhD fellowship from the Academy of Finland as part of the Graduate Program (TGPBB), University of Tampere, Finland. His thesis was heavily focused on understanding the mechanisms regulating the expression of a recently identified oncoprotein, CIP2A (Cancerous Inhibitor of Protein Phosphatase 2A) and its clinical relevance in human cancers. During his MD/PhD studies, he authored five manuscripts, three as first author. His projects have had translational implications and have been published in the leading journals of the field. In his first original research manuscript (Khanna et al, JNCI 2009), he identified a positive feedback loop between CIP2A and MYC, opened up opportunities to target MYC in human cancers without impacting the normal cell population. This work has been recognized globally, as evidenced by the international awards (EACR-Young Cancer Researcher Award, CELL Press Special Commendation Award) and the number of citations the paper has received. In his other major project, he delineated a mechanism by which constitutive DNA-damage promotes cancer growth. These findings, also holding significant translational relevance, have captured the attention of both the academia and the industry. The Scientist of the Year (2011) Award- Finland and the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award at the annual AACR meeting in Orlando, USA, and special highlight by Nature-SciBX are a testimony to this. My pioneering work has resulted in invitations to write the first comprehensive review on CIP2A in 2013 for Cancer Research, the most cited cancer research journal. Lately, he received the prestigious NHMRC-project grant (role CIA) and NHMRC-Peter-Doherty early career fellowship for executing his ideas on combatting Glioblastoma. In summary, his research experience includes actual translational discoveries (novel oncogenic pathways and targets), validation (in human tumours) and prospective commercialization (patents) of discoveries.

Research Interest

His general research interests include: Carcinogenesis and Drug resistance and Specific areas of interests include DNA-damage, Cancer Stem cells, Kinases and Phosphatases, Solid tumours like ovarian tumours, Breast tumours, Glioblastoma, Prostate cancer and Neuroblastomas.

Scientific Activities


• (2015-2018) the prestigious NHMRC (Peter Doherty) Early Career Biomedical Fellowship
• (2014) ComBio 2014 Early Career Researcher Award, Canberra, Australia
• (2012) Finalist for Thompson Prize, Sydney Protein Group, University of Western Sydney, Sydney, Australia
• (2011) Voted the Scientist of the Year-Finnish Union of University Researchers and Teachers (FUURT), Helsinki, Finland
• (2011) The American Association for Cancer Research (AACR)-GlaxoSmithKline Outstanding Clinical Scholar Award, at the 102nd Annual Meeting, Orlando, Florida, USA
• (2010) European Association for Cancer Research (EACR) Meeting Bursaries: EACR-21, Oslo, Norway, Meeting Bursary Award Winner
• (2010) Nomination for the British Association for Cancer Research (BACR) Hamilton Fairley Young Investigator Award at the National Cancer Research Institute (NCRI), Liverpool, UK
• (2010) Selected for the International Talent Program (ITP) for Life Sciences & Health-Ministry of Economic Affairs Innovation Program for Life Sciences & Health, Amsterdam, Netherlands
• (2010) Best poster presentation-TGSBB-Summer School, Muurikka, University of Tampere, organised by Prof. Howy Jacobs (head of the graduate school)
• (2009) European Association for Cancer Research (EACR) Symposium Bursary: “Transcription & Cancer”, University of Cambridge, United Kingdom
• (2009) The prestigious European Association for Cancer Research (EACR) Young Cancer Researcher Award – Highly Commended at ECCO 15 -34 ESMO, Berlin, Germany
• (2008) European Association for Cancer Research (EACR) Meeting Bursaries: EACR-20 Lyon, France – Meeting Bursary Award Winner
• (2008) CELL Press Special Commendation Award for Highest scored abstract, EACR-20, France
• (2008) Pezcoller Best Poster Prize: EACR-20, Lyon, France


• (2010-2012) British Association for Cancer Research (BACR)
• (2010-2012) The Finnish Biochemical, Biophysics and Microbiology Society (part of FEBS)
• (2013-Present) Australian Society for Biochemistry and Molecular Biology (ASBMB)
• (2012-Present) Sydney Protein Group (SPG)
• (2009-Present) American Association for Cancer Research (AACR)
• (2011-Present) American Society for Clinical Oncology (ASCO)
• (2009-Present) European Society for Medical Oncology (ESMO)
• (2008-Present) European Association for Cancer Research (EACR)
• (2012-Present) Clinical Oncology Society of Australia (COSA)



1. Khanna A, Bockelman C, Hemmes A, et al. C-Myc-dependent regulation and prognostic role of CIP2A in gastric cancer. Journal of the National Cancer Institute. 2009; 101: 793-805.
2. Khanna A, Okkeri J, Westermarck J. Atlas of Genetics and Cytogenetics in Oncology and Haematology. KIAA1524. 2010; 14 (10): 976-978.
3. Khanna A, Okkeri J, Bilgen T, et al. Ets-1 mediates MEK–dependent CIP2A expression in human cancers. PLoS one. 2011; 6(3): e17979. doi: 10.1371/journal.pone.0017979
4. Mathiasen D, Egebjerg C, Andersen SH, et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene. 2012; 31(3): 390-401. doi: 10.1038/onc.2011.230
5. Laine A, Sihto H, Come C, et al. E2F1- CIP2A feedback loop prevents senescence induction in breast cancer cells with inactive p53. Cancer Discovery. 2013. doi: 10.1158/2159-8290.CD-12-0292.
6. Khanna A, Kauko O, Böckelman C, et al. CHK1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Research. 2013. doi: 10.1158/0008-5472.CAN-13-1002
7. Khanna A, Pimanda JE, Westermarck J. Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A): An endogenous inhibitor of PP2A complex and an emerging oncogene. Cancer Research. 2013; 3(22): 6548-6553. doi: 10.1158/0008-5472.CAN-13-1994
8. Khanna A. Regulation of Cancerous inhibitor of PP2A (CIP2A) by small molecule inhibitor for c-Jun NH 2-Terminal Kinases (JNKs), SP600125, in Human Fibrosarcoma (HT1080) cells. F1000Research. 2013; 2: 174. doi: 10.12688/f1000research.2-174.v2
9. Khanna A, Patil R, Deshmukh A. Assessment of the Potential of Pathological Stains in Prostate Cancer. Journal of Clinical and Diagnostic Research. 2014; 8 (1): 124-128. doi: